Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer?

Şimşek, Duygu Has; Şanlı, Yasemin; Civan, Caner; Engin, Müge Nur; Işık, Emine Göknur; Özkan, Zeynep Gözde; Kuyumcu, Serkan

doi:10.1007/s12149-020-01474-7

Cited by 21 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, we noticed a relatively low equivocal examination rate, with only 7 patients (6%) classified as doubtful for the presence of bone metastases, while the remaining patients were immediately categorized as positive or negative. These results are in accordance with those of Helyar et al who reported an 8% rate of equivocal lesions according to SPECT/CT and a significantly reduced rate of equivocal lesions in comparison with that of planar BS alone [40].…”

Section: Diagnostic Performance Of Whole-body Bone Spect/ctsupporting

confidence: 93%

“…PSMA has recently become a very promising target for the diagnostic and therapeutic management of patients with PC. PSMA-PET/CT was shown to outperform planar BS and bone SPECT/CT for the detection of bone metastases [24,40] and FCH PET/CT for the number of detected bone metastases and for the overall number of identified recurrence sites [22], especially in patients presenting with low, < 2 ng/mL PSA levels. Indeed, the AUC of WB bone SPECT/CT and FCH PET/CT were comparable in our study and both were equivalent to the AUC observed by Pyka et al [24] for WB bone SPECT/CT whereas the authors found a significantly better AUC for PSMA PET/CT.…”

Section: Perspectivementioning

confidence: 99%

See 1 more Smart Citation

Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

et al. 2020

View full text Add to dashboard Cite

Background: To assess whether whole-body (WB) bone SPECT/CT provides additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence (PC-BR). Methods: Patients referred for a PC-BR and whom benefited from a WB bone SPECT/CT and FCH PET/CT were retrospectively included. Tests were classified as positive, equivocal, or negative for bone metastases. A best valuable comparator (BVC) strategy including imaging and follow-up data was used to determine the metastatic status in the absence of systematic histological evaluation. Results: Between January 2011 and November 2017, 115 consecutive patients with a PC-BR were evaluated. According to the BVC, 30 patients had bone metastases and 85 patients did not present with bone lesions. The sensitivity, specificity, positive and negative predictive values were respectively 86.7% [69.3-96.2], 98.8% [93.6-100.0], 96.3% [78.7-99.5], and 95.5% [89.4-98.1] for WB bone SPECT/CT and 93.3% [77.9-99.2], 100.0% [95.8-100.0], 100.0 and 97.7% [91.8-99.4] for FCH PET/CT. There was no significant difference in diagnostic accuracy of bone metastases between WB Bone SPECT/CT (AUC 0.824 [0.74-0.90]) and FCH PET/CT (AUC 0.829 [0.75-0.90], p = 0.41). Conclusion: Despite good performances for the diagnosis of bone metastases in PC-BR, WB bone SPECT/CT does not provide additive diagnostic information over concomitant FCH PET/CT.

show abstract

Section: Diagnostic Performance Of Whole-body Bone Spect/ctsupporting

confidence: 93%

Section: Perspectivementioning

confidence: 99%

Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, local staging is limited to surgery field, and distant metastases are frequently missed with standard imaging modalities which have limited sensitivity for PCa metastasis (4,5,27). The diagnostic superiority of PSMA PET has been shown in comparison studies previously (9,28,29). In agreement with those studies, PSMA PET showed at least one local/metastatic lesion in 64.5% of patients with persisting detectable PSA after RP in a prospective study (30).…”

Section: Discussionsupporting

confidence: 52%

“…Overall, PSMA PET had an impact on therapy management in 23.9% of patients, even where abdominopelvic imaging and BS were present. Recently, we published a comparative study revealing that PSMA PET has significantly higher sensitivity and specificity for detection of BS, compared with BS and BS+SPECT/ CT (9). The sensitivity and specificity were 100-97.7% for PSMA PET in the staging group, 38.8-51.1% for BS and 428-81.8% for BS+SPECT/CT based on lesion analysis, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Ultimately, 68Ga-PSMA PET/ CT (PSMA PET) has entered the clinical practice, using prostate-specific membrane antigen (PSMA) as a target protein, which is significantly overexpressed in most of PCa cases (6). Up to now, PSMA PET has been shown to be superior to cross-sectional abdominopelvic imaging and bone scan for detection of PCa metastasis (7)(8)(9). Since the excellent results of PSMA PET were published, recent EAU Guideline have recommended PSMA PET for biochemical recurrence (BCR), however, they still recommend cross-sectional abdominopelvic imaging and bone scan for staging intermediate and high-risk PCa, due to the unclear results (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Yüksek Ri̇skli̇ Prostat Kanseri̇nde 68ga-Psma Pet/Bt’ni̇n Tedavi̇ Yöneti̇mi̇ne Etki̇si̇

Şimşek¹,

Işık²,

Civan³

et al. 2021

J Istanb Fac Med

Self Cite

View full text Add to dashboard Cite

Yüksek riskli prostat kanserinde (PK) 68Ga-PSMA PET/ BT'nin (PSMA PET) tedavi yönetimine etkisi değerlendirildi. Gereç ve Yöntem: Yüksek riskli PK nedeniyle evreleme amaçlı PSMA PET yapılan hastalar retrospektif olarak değerlendirildi. Hastaların PSMA PET öncesi abdominopelvik BT (n=126), pelvik MR (n=42) ve kemik sintigrafisi (KS) (n=40) bulunmaktaydı. Tüm klinik, biyokimya ve görüntüleme datası belgelendi. Hastalara uygulanan tedavilerin incelenmesi amacıyla hastalar takibe alındı. PK ile ilişkili artmış PSMA tutulumları önceden PSMA-RADS versiyon 1,0'da tanımlanan 5 puanlı skalaya göre belgelendi. PSMA PET'in hasta yönetimine etkisi pre-post PET/BT anketler ile retrospektif olarak değerlendirildi. PSMA PET sonuçlarına göre yönetim değişikliği inter ve intramodalite değişiklik olarak kategorize edildi. Altgruplar eşleştirilmiş t-testi ile SPSS version 24,0 programında karşılaştırıldı. p değeri <0,05 anlamlı kabul edildi. Bulgular: Toplam 126 hasta çalışmaya dahil edildi. Medyan PSA değeri 30,8 ng/ml (%95CI: 2,1-268,6 ng/ml) ve medyan GS 8 (range: 6-10) idi. PSMA PET sonuçlarına göre 41 hastada (%32,5) hastalık daha çok yaygın iken, 2 hastada (%1,6) daha az yaygın idi. Toplamda tedavi yönetimi 38 hastada (%30,1) değişti. Intermodalite değişiklik 29 hastada (%23) görülürken, intramodalite değişiklik 9 hastada (%7,1) görüldü. Yönetimdeki değişiklik KS olan ve olmayan grupta, %30 ve %30,2 ile benzerdi. Sonuç: PSMA PET yüksek riskli PK'de hastalar standart görüntülemeler ile evrelense bile neredeyse üçte birinde tedavi yönetimini etkilemektedir.

show abstract

Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level

et al. 2022

View full text Add to dashboard Cite

Background:The numbers needed to image to identify pelvic lymph node and/or distant metastases in newly diagnosed prostate cancer (PCa) patients according to risk level are unknown. Methods: Relying on Surveillance, Epidemiology, and End Results (2010-2016), we tabulated rates and proportions of patients with (a) lymph node or (b) distant metastases according to National Comprehensive Cancer Network (NCCN) risk level and calculated the number needed to image (NNI) for both endpoints. Multivariable logistic regression analyses were performed.Results: Of 145,939 newly diagnosed PCa patients assessable for analyses of pelvic lymph node metastases (cN1), 4559 (3.1%) harbored cN1 stage: 13 (0.02%), 18 (0.08%), 63 (0.3%), 512 (2.8%), and 3954 (14.9%) in low, intermediate favorable,

show abstract

Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer?

Cited by 21 publications

References 30 publications

Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Yüksek Ri̇skli̇ Prostat Kanseri̇nde 68ga-Psma Pet/Bt’ni̇n Tedavi̇ Yöneti̇mi̇ne Etki̇si̇

Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level

Contact Info

Product

Resources

About